Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients  Tao Jiang, Shengxiang.

Similar presentations


Presentation on theme: "P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients  Tao Jiang, Shengxiang."— Presentation transcript:

1 P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients  Tao Jiang, Shengxiang Ren, Caicun Zhou  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S1235-S1236 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S1235-S1236DOI: (10.1016/j.jtho.2016.11.1742)
Copyright © Terms and Conditions

3 Journal of Thoracic Oncology 2017 12, S1235-S1236DOI: (10.1016/j.jtho.2016.11.1742)
Copyright © Terms and Conditions


Download ppt "P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients  Tao Jiang, Shengxiang."

Similar presentations


Ads by Google